Con game: What happens when people are overly concerned they may be suckered Greg Miller | September 10, 2026 (+++)

Con game: What happens when people are overly concerned they may be suckered Greg Miller | September 10, 2026 https://geneticliteracyproject.org/2026/09/10/con-game-what-happens-when-people-are-overly-concerned-they-may-be-suckered/ From smart packaging to bio-based coatings, scientists find new ways to reduce food contamination Mariella Bodemeier Loayza Careaga | September 8, 2026 https://geneticliteracyproject.org/2026/09/08/from-smart-packaging-to-bio-based-coatings-scientists-find-new-ways-to-reduce-food-contamination/ Allergic to dogs? A CRISPR solution may be in the works Laura Dattaro | September 10, 2026 https://geneticliteracyproject.org/2026/09/10/allergic-to-dogs-a-crispr-solution-may-be-in-the-works/

Science Literacy Project Daily Digest Science Controversies in the Media (++++ ++++)

Science Literacy Project Daily Digest Science Controversies in the Media Facing ridicule, Hegseth rescinds Pentagon’s new testosterone mandates ABC News https://geneticliteracyproject.org/2026/09/10/facing-ridicule-hegseth-rescinds-pentagons-new-testosterone-mandates/ Chemophobia trap: How the ‘appeal to nature’ fallacy makes ‘clean’ and organic products seem safer—even when they’re not Huffington Post https://geneticliteracyproject.org/2026/09/10/chemophobia-trap-how-the-appeal-to-nature-fallacy-makes-clean-and-organic-products-seem-safer-even-when-theyre-not/ Flattening culture and cognition: Is AI eroding our singularity? Nature https://geneticliteracyproject.org/2026/09/10/flattening-culture-and-cognition-is-ai-eroding-our-singularity/ Viewpoint: Cocky but wrong—feeling superior feeds medical and health conspiracy theories Glendale Star https://geneticliteracyproject.org/2026/09/10/viewpoint-cocky-but-wrong-feeling-superior-feeds-medical-and-health-conspiracy-theories/ Social media still eclipses AI as the driving force of medical misinformation Tech Target https://geneticliteracyproject.org/2026/09/09/social-media-still-eclipses-ai-as-the-driving-force-of-medical-misinformation/ Public is skeptical about claims of vaccine danger, but a poll shows troubling doubts Laine Bergeson | CIDRAP https://geneticliteracyproject.org/2026/09/09/public-is-skeptical-about-claims-of-vaccine-danger-but-a-poll-shows-troubling-doubts/ The promise and peril of gene editing MedPage Today https://geneticliteracyproject.org/2026/09/09/the-promise-and-peril-of-gene-editing/ Viewpoint: How to challenge the lucrative health fear-mongering business STAT News https://geneticliteracyproject.org/2026/09/09/viewpoint-how-to-challenge-the-lucrative-health-fear-mongering-business/

Lead Generation and Aligning Sales and Marketing: What’s Changed, What's Working, What's Not, and Best Practices September 29th, 2026 at 9:00 am PDT / 12:00 pm EDT / 5:00 pm BST / 6:00 pm CEST

https://pages.labxmediagroup.com/lead-generation-and-aligning-sales-and-marketing?hsCtaAttrib=220282661392 Lead generation in the life sciences isn't broken—but the landscape has changed significantly, and many of the standard practices haven't kept pace. How prospects prefer to communicate is different: increasingly, people want to be reached via SMS, WhatsApp, and other modern channels that many  commercial sales teams don't routinely use. Standard modes of follow-up aren't inherently flawed—they're simply no longer aligned with how today's buyers operate.  As a result, vendors are losing pipeline at multiple stages: in campaign and landing page configuration, in the qualification criteria applied before a lead is even accepted, in lead classification, and in what happens after the form is filled—which, too often, is not enough. Too few sales reps make a concerted effort to follow up with the consistency that converting a lead requires. The fallout is a widening divide between sales and marketing: marketing generates leads it considers legitimate, sales dismiss them as low quality, and prospects—unreached through the right channels—simply don't respond.  In this panel discussion, experts from LabX Media Group and JBC Associates draw on data from thousands of campaigns and decades of frontline commercial experience to examine common mistakes and practical fixes across the full lead generation journey. 

Why the best drug candidates get missed by narrow screens Starting from a defined mechanism can cause discovery programs to miss the best drug candidates. Written byAndrea Corona

Why the best drug candidates get missed by narrow screens Starting from a defined mechanism can cause discovery programs to miss the best drug candidates. Written byAndrea Corona https://www.drugdiscoverynews.com/why-the-best-drug-candidates-get-missed-by-narrow-screens-17494?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-98Glw7Y64mq7yYTRtyw4rkIvPngGYLswQIhomzYmmP3l39q-xE8eFGrJcFoJSZh9fOi3umPOuFHL0-6K6kK4gWfHEFew&_hsmi=438341142&utm_content=438341142&utm_source=hs_email Most degrader discovery programs start with a hypothesis: pick the target, pick the E3 ligase, pick a binding pocket, then screen for a molecule that connects them. Matthias Brand, cofounder and Chief Technology Officer of Proxygen, told DDN that approach can cause programs to miss their best candidates before they're found.

Fabry Disease: Patients' Real-World Problems and How to Manage Them

Follow-Up Data of Safusidenib in Patients With IDH-Mutant Gliomas by Madaline Spencer| Published on: Aug 14, 2026

Follow-Up Data of Safusidenib in Patients With IDH-Mutant Gliomas by Madaline Spencer| Published on: Aug 14, 2026 Alexandra Miller, MD, PhD, Chief of Neuro-Oncology and Co-Director of the Brain and Spine Tumor Center at the Perlmutter Cancer Center at NYU Langone Health, discusses follow-up data on the safety and efficacy of safusidenib in patients with IDH-mutant gliomas. https://checkrare.com/follow-up-data-of-safusidenib-in-patients-with-idh-mutant-gliomas/

Beyond AChR: Recognizing and Treating MuSK Ab+, LRP4 Ab+ and Triple Seronegative Myasthenia Gravis

https://checkrare.com/learning/p-beyond-achr-recognizing-and-treating-musk-ab-lrp4-ab-and-triple-seronegative-myasthenia-gravis/ This accredited CME program examines best practices to diagnose and treat patients with ultra-rare forms of myasthenia gravis. The most prevalent form of myasthenia gravis is associated with antibodies against the acetylcholine receptor (AChR Ab+). However, 15- 20% of patients with myasthenia gravis are not AChR Ab+. These clinically important and underrecognized subsets of patients harbor antibodies against muscle-specific kinase (MuSK Ab+) lipoprotein receptor-related protein 4 (LRP4 Ab+), or test negative for all known antibodies (triple seronegative MG). These patients present unique diagnostic and treatment challenges that necessitate expert guidance to improve their management.